A new micromethod for the in vitro detection of antiplatelet antibodies: C-FDA thrombocytotoxicity

Hum Immunol. 1980 Jul;1(1):87-96. doi: 10.1016/0198-8859(80)90012-9.


A new microtechnique, C-FDA, for the in vitro detection of antiplatelet antibodies, is described. This technique is faster and simpler than either 51Cr thrombocytotoxicity or immunofluorescence (IF). C-FDA is more sensitive than 51Cr for all (anti-HLA, --P1A1, ABO, drug-related, and ITP-related) antibodies tested. Although IF was more sensitive for many types of antibodies, C-FDA was as good or better a clinical test method for all drug-related and isoimmune neonatal thrombocytopenia patient sera tested. Preliminary data also suggest that this method detects possible new non-HLA, non-ABO, nonP1A1 platelet antigens.

MeSH terms

  • ABO Blood-Group System
  • Antibodies*
  • Blood Platelets / immunology*
  • Chromium Radioisotopes
  • Cytotoxicity Tests, Immunologic / methods
  • Epitopes
  • False Negative Reactions
  • False Positive Reactions
  • Female
  • Fluorescent Antibody Technique
  • Humans
  • Male
  • Thrombocytopenia / immunology


  • ABO Blood-Group System
  • Antibodies
  • Chromium Radioisotopes
  • Epitopes